Diabetes Management in the Oldest Old: De-Intensification, CGM, and Polypharmacy | Market Intelligence

Description

List of Tables

Managing diabetes in an 85-year-old is a different discipline from managing it at 55, and Japan has more of those patients than anywhere else. The country's oldest-old population lives with type 2 diabetes at body weights far below Western trial populations, with frailty, cognitive decline, and polypharmacy layered on top. Japanese geriatric-diabetes guidance reflects this: glycemic targets are stratified by functional status, de-intensification is an explicit treatment maneuver rather than a concession, and hypoglycemia avoidance takes precedence over tight control. Western-centric guidance, built on different populations, translates poorly.

Three commercial battlegrounds sit inside this clinical reality. First, continuous glucose monitoring: CGM adoption in elderly insulin users is the device industry's clearest growth frontier in Japan, with Abbott's FreeStyle Libre franchise and Dexcom's sensors, distributed by Terumo, competing on form factor, alarm design, and reimbursement coverage, while Medtronic, Senseonics, and low-cost Chinese entrants press the edges. Second, de-intensification itself: deprescribing sulfonylureas and simplifying insulin regimens changes volumes for Novo Nordisk, Lilly, and Sanofi even as it improves safety. Third, polypharmacy management, where diabetes drugs intersect with everything else an elderly patient takes, and where structured review is still rare.

This report maps the segment end to end. It covers the epidemiology of diabetes in Japan's oldest old and how it differs from Western populations; the Japanese guideline framework and its stratified target structure; the pharmacotherapy landscape from basal insulins to GLP-1 agents and tirzepatide in elderly use; the monitoring landscape across CGM, SMBG, and point-of-care HbA1c with Abbott, Dexcom-Terumo, Roche, Arkray, and Sinocare; the delivery-device layer including Medtronic, Insulet, Tandem, Terumo, Nipro, and Ypsomed; and the reimbursement rules that govern CGM and pump coverage under NHI. US, EU5, and China chapters provide comparison.

The report serves CGM and pump manufacturers planning elderly-market strategy, pharma companies managing elderly-diabetes franchises, payers and policymakers weighing monitoring coverage, care providers building protocols, and investors. It is organized so that device, drug, and policy readers each get a complete account without reading the whole volume.

Scope and Coverage

The report covers type 2 diabetes management in the oldest-old population across the US, EU5, Japan, and China: guideline frameworks, pharmacotherapy, glucose-monitoring and delivery devices, de-intensification and polypharmacy practice, and NHI reimbursement. Type 1 diabetes and pediatric populations are outside scope.

Report Highlights

Japanese geriatric-diabetes guideline framework and stratified target structure
Population differences between Japanese and Western elderly diabetes cohorts
CGM competitive landscape: Abbott, Dexcom-Terumo, Medtronic, Senseonics, and Sinocare
De-intensification practice and its implications for insulin and sulfonylurea franchises
Polypharmacy management structures and their gaps
NHI reimbursement rules for CGM, pumps, and elderly diabetes care

Product Code: JPH-015

Table of Content

1. Executive Summary

2. Diabetes Management in the Oldest Old: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

Abbott (US) - FreeStyle Libre CGM family, leading sensor franchise in Japan
Dexcom (US) - G6/G7 CGM distributed in Japan via Terumo
Medtronic (US) - integrated pump-CGM systems in the Japanese diabetes unit
Senseonics (US) - Eversense implantable CGM
Roche (CH) - Accu-Chek SMBG legacy installed base
Sinocare (CN) - low-cost CGM and SMBG expansion across Asia
Terumo (JP) - Medisafe insulin pumps and pens; Dexcom Japan distributor
Arkray (JP) - Glucocard SMBG and point-of-care HbA1c systems
Nipro (JP) - insulin needles and diabetes consumables
Insulet (US) - Omnipod tubeless pump
Tandem (US) - t:slim automated-insulin-delivery systems
Novo Nordisk (DK) - basal insulins and GLP-1 agents used in elderly T2D
Eli Lilly (US) - tirzepatide and insulin portfolio
Sanofi (FR) - Toujeo basal-insulin legacy franchise
Ypsomed (CH) - pen needles and pump-component supply

Product Code: JPH-015

List of Tables

Table 1. Diabetes in the oldest old: clinical framework and age-band definitions
Table 2. Japanese geriatric-diabetes guideline structure: functional-status categories and targets
Table 3. International guideline comparison: ADA, EASD, and Chinese geriatric positions
Table 4. Milestones in Japanese elderly-diabetes practice and policy by year
Table 5. Oldest-old diabetes population structure by care setting
Table 6. Body-composition and phenotype differences between Japanese and Western cohorts
Table 7. Frailty, cognitive decline, and functional-status frameworks in diabetes care
Table 8. Polypharmacy structure in elderly Japanese diabetes patients
Table 9. Hypoglycemia-risk framework and its drivers in the oldest old
Table 10. Current pharmacotherapy landscape: class positions in elderly practice
Table 11. Basal-insulin regimens: Novo Nordisk, Lilly, and Sanofi Toujeo positioning
Table 12. GLP-1 agents and tirzepatide in elderly Japanese patients
Table 13. SGLT2 inhibitor use considerations in frail elderly diabetes
Table 14. Sulfonylurea and glinide legacy use and deprescribing frameworks
Table 15. De-intensification protocols: simplification of insulin and oral regimens
Table 16. FreeStyle Libre family (Abbott): sensor generations and Japan positioning
Table 17. Dexcom G6 and G7 in Japan: Terumo distribution structure
Table 18. Medtronic integrated pump-CGM systems in the Japanese diabetes unit
Table 19. Senseonics Eversense implantable CGM status
Table 20. Sinocare low-cost CGM and SMBG expansion across Asia
Table 21. Roche Accu-Chek SMBG installed base in elderly care
Table 22. Arkray Glucocard SMBG and point-of-care HbA1c systems
Table 23. Terumo Medisafe insulin pumps and pens
Table 24. Insulet Omnipod and Tandem t:slim automated-delivery systems: Japan status
Table 25. Nipro insulin needles and Ypsomed pen-needle and pump-component supply
Table 26. PMDA device-approval pathway for CGM and insulin-delivery systems
Table 27. FDA OTC-CGM and EU MDR pathway comparison
Table 28. China NMPA pathway and domestic CGM competition
Table 29. Interoperability and data-standards frameworks for diabetes devices
Table 30. NHI reimbursement structure for CGM: coverage categories and eligibility
Table 31. NHI reimbursement for insulin pumps and automated delivery
Table 32. SMBG strip reimbursement structure for elderly patients
Table 33. Medical-fee framework for elderly diabetes management in outpatient care
Table 34. US Medicare CGM coverage comparison
Table 35. EU5 and China payment environments for glucose monitoring
Table 36. Abbott: Libre franchise organization and elderly-market strategy
Table 37. Dexcom and Terumo: Japan distribution and competitive structure
Table 38. Medtronic and Senseonics: system-based positioning
Table 39. Roche, Arkray, and Sinocare: SMBG and value-tier competition
Table 40. Novo Nordisk, Lilly, and Sanofi: insulin and incretin franchises in elderly care
Table 41. Terumo, Nipro, and Ypsomed: delivery-device and consumable positions
Table 42. Care-home and home-care settings as diabetes-device channels
Table 43. Unmet needs: hypoglycemia detection and alarm design for cognitively impaired users
Table 44. De-intensification decision-support opportunities
Table 45. CGM expansion pathways beyond insulin users in the oldest old
Table 46. Care-setting protocol opportunities: nursing facilities and home care
Table 47. Polypharmacy-review service models and their sponsors
Table 48. Policy agenda: monitoring coverage expansion and geriatric-diabetes programs
Table 49. Report methodology: guideline analysis, device documentation, and interview base
Table 50. Glossary of devices, drug classes, and guideline terms

List of Figures

Figure 1. Oldest-old diabetes clinical framework diagram
Figure 2. Japanese guideline stratification structure by functional status
Figure 3. International geriatric-diabetes guideline comparison map
Figure 4. Japanese elderly-diabetes practice timeline
Figure 5. Oldest-old diabetes population map by care setting
Figure 6. Japanese versus Western phenotype comparison framework
Figure 7. Frailty and functional-status framework in diabetes care
Figure 8. Polypharmacy structure schematic
Figure 9. Hypoglycemia-risk driver map
Figure 10. Pharmacotherapy class-position landscape in elderly practice
Figure 11. Basal-insulin regimen positioning map
Figure 12. GLP-1 and tirzepatide elderly-use pathway
Figure 13. SGLT2 inhibitor consideration framework in frail patients
Figure 14. Sulfonylurea deprescribing pathway
Figure 15. De-intensification protocol flow
Figure 16. FreeStyle Libre generation map
Figure 17. Dexcom-Terumo Japan distribution structure
Figure 18. Medtronic integrated-system architecture
Figure 19. Eversense implantable CGM status diagram
Figure 20. Sinocare value-tier expansion map
Figure 21. Accu-Chek installed-base structure
Figure 22. Arkray SMBG and HbA1c system map
Figure 23. Terumo Medisafe delivery-device lineup
Figure 24. Omnipod and t:slim Japan status diagram
Figure 25. Needle and component supply structure: Nipro and Ypsomed
Figure 26. PMDA device-approval flow for CGM and pumps
Figure 27. FDA and EU MDR pathway comparison map
Figure 28. NMPA pathway and domestic CGM competition map
Figure 29. Device interoperability and data-standards framework
Figure 30. NHI CGM coverage decision structure
Figure 31. Pump and automated-delivery reimbursement flow
Figure 32. SMBG strip reimbursement structure
Figure 33. Outpatient management fee framework
Figure 34. Medicare CGM coverage comparison diagram
Figure 35. EU5 and China payment environment map
Figure 36. Abbott Libre organization and strategy map
Figure 37. Dexcom-Terumo competitive structure diagram
Figure 38. Medtronic and Senseonics positioning map
Figure 39. SMBG and value-tier competition landscape
Figure 40. Insulin and incretin franchise positions in elderly care
Figure 41. Delivery-device and consumable position map
Figure 42. Care-setting channel structure for diabetes devices
Figure 43. Unmet-need map: alarms and cognitive impairment
Figure 44. De-intensification decision-support opportunity map
Figure 45. CGM expansion pathway schematic
Figure 46. Care-setting protocol opportunity map
Figure 47. Polypharmacy-review service model diagram
Figure 48. Policy lever map for monitoring coverage
Figure 49. Methodology flow: guidelines, devices, interviews
Figure 50. Data cut-off and update cadence schematic

Diabetes Management in the Oldest Old: De-Intensification, CGM, and Polypharmacy | Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Diabetes Management in the Oldest Old: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures